Overview

• Shipments of Elevidys have been halted for non-ambulatory Duchenne muscular dystrophy patients pending approval of enhanced immunosuppression protocols.
• Dosing in a related Elevidys clinical trial has been paused to investigate safety and implement mitigation measures.
• Sarepta’s stock plunged nearly 40% in premarket trading following the company’s safety disclosures.
• Analysts at Piper Sandler and BMO Capital downgraded their ratings on Sarepta’s shares, citing heightened safety concerns.
• Elevidys generated $820.8 million in revenue in 2024 and was projected to bring in $1.5 billion in 2025, putting future earnings forecasts at risk.